International Edition
Latest News
Health

Sugar Could Defeat Deadly Superbugs: Scientists Discover New Treatment

Summary of the Research: New Antibody Targets Bacterial Sugar to Fight Drug-Resistant Infections This research details the advancement of a novel antibody that targets a unique bacterial sugar, pseudaminic acid, offering a promising new approach to combatting drug-resistant…

Sugar Could Defeat Deadly Superbugs: Scientists Discover New Treatment

Summary of the Research: New Antibody Targets Bacterial Sugar to Fight Drug-Resistant Infections

This research details the advancement of a novel antibody that targets a unique bacterial sugar, pseudaminic acid, offering a promising new approach to combatting drug-resistant bacterial infections. Here’s a breakdown of the key points:

* The Problem: Multidrug-resistant bacteria, like Acinetobacter baumannii, pose a significant threat in healthcare settings, often resisting even last-line antibiotics.
* The Innovation: Researchers created a “pan-specific” antibody that recognizes pseudaminic acid, a sugar found only on the surface of many hazardous bacteria. Because humans don’t produce this sugar, the antibody specifically targets bacteria without harming healthy cells.
* How it Works:

* The team synthesized the bacterial sugar in the lab to understand its structure.
* This knowledge allowed them to design an antibody that binds to the sugar with high specificity.
* In mouse studies, the antibody successfully cleared Acinetobacter baumannii infections.
* Passive Immunotherapy: This antibody is designed for passive immunotherapy – providing patients with ready-made antibodies to quickly fight infection, rather than relying on the body’s own immune response. This could be used for both treatment and prevention, notably in vulnerable hospital patients.
* Broader Implications: The antibody also provides a tool to study bacterial virulence and develop better diagnostics.
* Future Plans: the team aims to develop this antibody into a clinical treatment for multidrug-resistant A. baumannii within the next five years, supported by the new Australian Research Council Center of Excellence for Advanced Peptide and Protein Engineering.

Key Researchers Involved:

* Professor Richard Payne (University of Sydney) – Co-lead and director of the new ARC Centre of Excellence.
* Professor Ethan goddard Borger (WEHI) – Co-lead.
* Associate Professor Nichollas Scott (University of Melbourne & Peter Doherty Institute) – Contributed to understanding bacterial virulence.

This research represents a significant step forward in the fight against antimicrobial resistance by targeting a unique bacterial vulnerability.

About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”